

Express Mail Label No. EL302645404US

11



PATENT
Attorney Docket No. LEX-003

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT(S): *Gillies et al.*

SERIAL NUMBER: 09/256,156 GROUP NUMBER: 1644

FILING DATE: February 24, 1999 EXAMINER: J. Murphy

TITLE: ENHANCING THE CIRCULATING HALF LIFE OF
ANTIBODY-BASED FUSION PROTEINS

RESPONSE TO RESTRICTION REQUIREMENT

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

In the Office Action mailed from the U.S. Patent Office on April 10, 2000 for the above-identified patent application, the Examiner requires Applicants to restrict prosecution to one of two Groups of claims, each Group being said to recite a distinct invention. Specifically, Group I comprises claims 1-13 and 25, and Group II comprises claims 14-24 and 26.

Applicants provisionally elect, with traverse, to prosecute the invention of Group I (claims 1-13 and 25) directed to "an antibody-based fusion protein with an enhanced circulating half-life, classified in class 530, subclass 387.3."

Response to Restriction Requirement

U.S. Serial No. 09/256,156

Page 2

If the Examiner believes a conversation with Applicants' agent would be helpful in expediting prosecution of this application, the Examiner is invited to call the undersigned agent at (617) 248-7240.

Respectfully submitted,



Patrick R.H. Waller
Registration No. 41,418

Dated: June 12, 2000

TESTA, HURWITZ & THIBEAULT, LLP
High Street Tower
125 High Street
Boston, MA 02110

Tel: (617) 248-7240
Fax: (617) 248-7100

1014561